Janina Haar is a trained virologist and molecular biologist who holds a PhD from the German Cancer Research Center (DKFZ) and Ruperto Carola University of Heidelberg. After completing her PhD, Janina joined the laboratory of Prof. Dirk Grimm as a Postdoc where she was the leading scientist within an industry collaboration aiming at the development of improved liver-tropic AAV capsids for hemophilia treatment. She transitioned to industry for a second Postdoc at Boehringer Ingelheim where she focused on the optimization of inducible gene expression cassettes for AAV-based gene therapy. Subsequently, Janina worked for Vector BioPharma AG in Basel as Senior Scientist developing adenoviral vectors for immuno-oncology applications and further exploring regulatable gene therapies. Janina joined Revvity in April 2024, where she is currently leading the laboratory team at the Heidelberg site of Revvity Gene Delivery and supporting our collaborations for AAV-based gene therapy development.
Archives: Speakers
Michelle Fraser
Michelle is the Head of Cell and Gene Therapy at Revvity. In this role, Michelle steers the strategic direction and influences how Revvity showcases its diverse array of CGT capabilities, across products, contracted services and technology licensing, to facilitate the advancement and launch of innovative cell and gene therapies. Michelle has a PhD in mycology and a Graduate Diploma in Science and Technology Commercialization from the University of Adelaide. She was previously manager of Revvity’s base editing business and our next generation sequencing product portfolio.